Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 11/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.43 |
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6528620 | 0.95 | NPC1 (0.46) | LTB4R2TP53CES2CES1NPC1 | |
| SCHEMBL5068716 | 0.83 | ALDH1A1 (0.44) | LTB4R2TP53NPC1RAB9AOPRM1 | |
| Hydrochloric Acid SCHEMBL6557848 | 0.81 | ALDH1A1 (0.43) | LTB4R2TP53NPC1RAB9AOPRM1 | |
| SCHEMBL5143989 | 0.78 | ALDH1A1 (0.41) | TP53CES1NPC1RAB9APAX8 | |
| SCHEMBL7978813 | 0.78 | ALDH1A1 (0.55) | LTB4R2TP53CES2CES1NPC1 | |
| SCHEMBL10969535 | 0.78 | TP53 (0.53) | LTB4R2TP53CES2CES1NPC1 | |
| SCHEMBL5143986 | 0.78 | ALDH1A1 (0.41) | TP53CES1NPC1RAB9APAX8 | |
| SCHEMBL7458741 | 0.77 | POLQ (0.41) | TP53NPC1RAB9A | |
| SCHEMBL4590412 | 0.76 | ALDH1A1 (0.40) | TP53CES1NPC1RAB9APAX8 | |
| SCHEMBL6360336 | 0.76 | TP53 (0.51) | LTB4R2TP53CES2CES1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367700-B2 | Substituted 4-(1.2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2013-02-05 | — | — | US | disclosed |
| US-20100105722-A1 | Substituted 4,5,6,7-tetrahydrothienopyridines as KCNQ2/3 Modulators | GRUENENTHAL GMBH (DE) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105722-A1 | Substituted 4,5,6,7-tetrahydrothienopyridines as KCNQ2/3 Modulators | KCNQ1, KCNQ3, KCNQ2 | LTB4R2 315/4885TP53 4589/4885CES2 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.